Krystal Biotech, Inc. Common Stock
KRYSKrystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for dermatological and rare diseases. Established with the goal of advancing genetic medicine, it utilizes a proprietary viral vector platform to deliver gene therapies with the potential to treat conditions that have limited treatment options. The company's approach aims to provide targeted, durable treatments for patients suffering from various skin disorders and other genetic conditions.
Company News
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Krystal Biotech will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, with CEO Krish S. Krishnan hosting a fireside chat and investor meetings. The company has generated $97.8 million in Q3 VYJUVEK revenue and launched the product in multiple countries.
Exelixis' stock has gained 20.7% in the past three months, outperforming the industry and the broader market. The company's lead drug Cabometyx has maintained strong performance, and its pipeline progress is encouraging. Exelixis is also focused on expanding Cabometyx's label and diversifying its portfolio.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
